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ABSTRACT
Human esophagus carcinoma (EC) is one of the most common malignant tumors, especially in Africa and Asia
including China. In EC initiation and progression, genetic and epigenetic aberrations have been reported to play
a major role, but the underlying molecular mechanisms are largely unknown. In this study, the miR-30e levels
were analyzed in human EC tissues and TCGA databases, and the results demonstrated that miR-30e expression
in EC tissues was significantly decreased compared to adjacent normal tissues. To further investigate the role of
miR-30e in cancer cells, we found that forced expression of miR-30e dramatically inhibited cell proliferation,
invasion, tube formation, and colony formation of cancer cells. To determine the underlying mechanism of miR30e, we found that RPS6KB1 was a direct target of miR-30e by binding to its 3′-UTR, which was verified by
luciferase activity assay using reporters with wild-type miR-30e and its seed sequence mutant constructs and
Western blotting assay. In vivo experiment showed that miR-30e overexpression significantly inhibited tumor
growth and decreased RPS6KB1 expression in xenografts. In EC, high expression of RPS6KB1 in tumor tissues
indicated poor prognosis of patients with less survival rate. High levels of RPS6KB1 and low levels of miR-30e
closely correlated poor survival of patients with several other types of cancer. These findings show that miR30e and its target RPS6KB1 are important in cancer development and clinical outcomes, and miR-30e/RPS6KB1
is a potential future therapeutic pathway for EC intervention.

INTRODUCTION

overall 5-year survival rate for EC patients remains quite
low (10–20%) due to high systemic toxicity and drug
resistance to cancer treatment [4–6]. Recent studies have
reported that the major drivers of EC carcinogenesis and
progression are abnormal functions of the oncogenes or
tumor suppressors [7, 8]. However, details of the
molecular mechanism for EC development are still
unclear. Thus, further study in molecular basis of EC is
imperative to support the development of new therapeutic
strategies to improve clinical survival rate of EC patients.

Esophageal cancer (EC) is one of the most frequently
reported cancer-related deaths worldwide and its
incidence in Asian countries, such as certain areas of
China, has increased sharply during recent decades [1, 2].
Adenocarcinoma and squamous cell carcinoma are two
distinct subtypes of EC [3]. Despite recent progress in EC
diagnostic and therapeutic strategies such as surgery
combined with chemotherapy or radiation therapy, the
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MicroRNAs are a group of small non-coding RNA
molecules, typically 18 to 24 nucleotides, that regulate
gene expression by targeting 3′-untranslated regions
(UTRs) of potential gene mRNAs [9–11]. Multiple
studies have convincingly shown that miRNAs play
important roles in biological processes such as
inflammation, cell cycle, stress response, differentiation,
apoptosis and migration [12–14]. MiRNAs have been
observed to be aberrantly expressed in cancers and are
involved in the EC gene regulation [9, 15–18]. In
addition, miR-30e has been found to be downregulated
in several cancers including breast, hepatocellular and
bladder cancer [19–21], but the mechanism and role of
miR-30e in EC remains to be elucidated.

human esophageal carcinoma are not clear yet. We
analyzed expression levels of miR-30e in 46 pairs of
human esophageal carcinoma tissues and their
corresponding non-cancerous adjacent esophageal
tissues, and found that miR-30e levels were
significantly decreased in human esophageal carcinoma
tissues compared to those of adjacent normal tissues
(Figure 1A). We also analyzed relative expression
levels of miR-30e in 185 human esophageal carcinoma
tissues and 13 normal tissues in TCGA database
(https://xenabrowser.net/datapages/), and the results
also showed significantly downregulation of miR-30e in
human esophageal carcinoma tissues compared to
normal tissues (Figure 1B). To further confirm the
results, we used the GEO dataset to study miR-30e
expression levels in esophageal carcinoma tissues and
adjacent normal esophageal tissues (GSE67268,
https://www.ncbi.nlm.nih.gov/geo/), and found that
miR-30e levels were also decreased by 20-fold in
human esophageal carcinoma tissues compared to
normal adjacent esophageal tissues (Figure 1C).

The mitogen-activated serine/threonine-protein-kinase
ribosomal protein S6 kinase B1 (RPS6KB1), also known
as the S6K1, is associated with a variety of cellular
processes including glucose homeostasis, mRNA
processing, protein synthesis, cell proliferation, growth
response and other cellular signal transductions [22–24].
RPS6KB1 is activated by serine or threonine residue
phosphorylation at threonine 389, and most of its
substrates contain a consensus phosphorylation motif
(K/RXRXX/T), which is critical to its catalytic activity.
In human malignancies, the commonly observed
constitutive activation of RPS6KB1 indicates its potential
therapeutic role. In addition, Michele Pagano et al.
showed that protein kinase S6K1 rapidly phosphorylated
the tumor suppressor programmed cell death protein 4
(PDCD4) at Ser67 and subsequently degraded PDCD4
via the ubiquitin ligase SCF (betaTRCP) in response to
mitogens [25]. Furthermore, RPS6KB1-mediated Gli1 at
Ser84 (downstream hedgehog pathway effector)
phosphorylation
promoted
esophageal
cancer
development [26]. These results strongly indicate that
RPS6KB1 is a potential biomarker for cancer diagnosis
and an advantageous target for cancer treatment.

MiR-30e overexpression inhibited cell proliferation,
invasion, tube formation and colony formation of
cancer cells
To determine the role of miR-30e in cancer cells, we
overexpressed miR-30e in human esophageal cancer
Kyse30 cells and cervix cancer Hela cells, and found
that miR-30e forced expression inhibited the
proliferation of both types of cells (Figure 2A). MiR30e overexpression also decreased the cell invasion
ability of Kyse30 and Hela cells with the reduction of
50% and 40%, respectively, using Transwell assay
(Figure 2B). Similarly, we found that overexpression of
miR-30e inhibited tube formation, clonogenicity, and
colony formation capacities (Figure 2C–2E). These
results suggest that miR-30e downregulation in cancer
is functionally important, which is involved in the
increases of cancer cell proliferation, invasion, tube
formation and colony formation.

In this study, we plan to address: (a) whether miR-30e
expression is associated with EC incidence; (b) what direct
target of miR-30e is involved in EC; (c) what roles miR-30e
and its target have in cancer cell proliferation and tumor
growth; and (d) whether miR-30e/RPS6KB1 axis is
associated with overall survival rate in EC cancer patients.
The results of this study will be helpful to further understand
the molecular mechanisms of EC carcinogenesis and
provide potential targets for EC treatment in the future.

MiR-30e directly targeted and inhibited RPS6KB1
expression
To elucidate the underlying molecular mechanism by
which miR-30e serves as a tumor suppressor in cancer
cells, we used bioinformatics tools to identify its
potential target(s), and predicted that RPS6KB1 was a
potential target of miR-30e (Figure 3A). In order to
determine whether miR-30e directly targets RPS6KB1,
3′-untranslated region (UTR) sequences containing
wide-type or mutant miR-30e binding site of RPS6KB1
were cloned into the pmirGLO vector, respectively.
Kyse30 cells were co-transfected with reporter plasmids
and miR-30e or miR-NC. MiR-30e transfection

RESULTS
MiR-30e expression was downregulated in human
esophageal carcinoma tissues compared to adjacent
normal esophageal tissues
MiR-30e was reported to function as a tumor suppressor
in some cancers, but its expression level and role in
www.aging-us.com
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significantly inhibited luciferase activity of RPS6KB1
wild-type reporter, but not that of the RPS6KB1 mutant
reporter with change of 4 base pairs in the binding site
(Figure 3B). Western blotting assay showed that
overexpression of miR-30e significantly repressed
protein levels of RPS6KB1 (Figure 3C). Consistently,
overexpression of miR-30e inhibitor markedly induced
RPS6KB1 expression (Figure 3D). Finally, we analyzed
the relationship between miR-30e and RPS6KB1 in
several
types
of
cancers
(http://www.linkedomics.org/admin.php). The results
(Supplementary Figure 1) showed that miR-30e
expression level negatively correlated to RPS6KB1
level in invasive breast carcinoma (BRCA),
glioblastoma
multiforme
(GBM),
and
lung
adenocarcinoma (LUAD). Overall, the results suggest

that miR-30e inhibits RPS6KB1 expression through
directly targeting its 3′-UTR.
MiR-30e overexpression inhibited tumor growth and
RPS6KB1 expression, and higher RPS6KB1
expression levels were associated with lower
esophageal cancer survival rate
To further understand the role of miR-30e in tumor
growth, Kyse30 cells were transduced by lentivirus
expressing miR-30e or negative control (miR-NC).
After the selection of cells in the presence of puromycin
for 2 weeks, cell lines stably expressing miR-NC and
miR-30e, termed as Kyse30/miR-NC and Kyse30/miR30e respectively, were established and confirmed. The
cells were injected into posterior flanks of

Figure 1. MiR-30e expression was downregulated in human esophageal carcinoma tissues compared to normal adjacent
esophageal tissues. (A) The relative expression levels of miR-30e were detected by qRT-PCR and normalized to an endogenous control
(U6 RNA) in 46 pairs of human esophageal carcinoma tissues. The results represent the ratio of miR-30e levels in tumor tissues to adjacent
normal tissues. (B) Relative expression levels of miR-30e in of 185 human esophageal carcinoma tissues were compared with 13 normal
tissues in TCGA database (https://xenabrowser.net/datapages/). (C) The miR-30e expression levels of adjacent normal esophageal tissues
and esophageal carcinoma tissues were analyzed in the public GEO dataset (GSE67268, https://www.ncbi.nlm.nih.gov/geo/). Data
represent mean ± SD of 3 replicates. *indicates significant difference at P < 0.05; **indicates significant difference at P < 0.01.
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immune-deficient mice, and tumor sizes were measured
starting on Day 12 after implantation. Compared to
miR-NC group, miR-30e-expressing group developed
significantly smaller tumors from Day 12 to Day 27
(Figure 4A–4C). Consistent with tumor growth results,
the protein levels of RPS6KB1 in tumor tissues from
miR-30e overexpression group were much lower than
those from miR-NC group analyzed by Western blotting
assay (Figure 4D). Moreover, the xenografts from miR30e-overexpressing Kyse30 cells showed lower

expression levels of PCNA by IHC staining compared
to control (Figure 4E), demonstrating that forced
expression of miR-30e inhibited tumor cell
proliferation. To further determine whether the
expression of miR-30e novel target RPS6KB1 is
relevant with human esophageal cancer, we studied
expression levels of RPS6KB1 in the cancer tissues and
the cancer outcome. We found that higher RPS6KB1
expression levels were strongly associated with lower
overall survival rate of esophageal adenocarcinoma and

Figure 2. MiR-30e overexpression inhibited cell proliferation, invasion, tube formation and colony formation of cancer
cells. (A) Human esophageal cancer Kyse30 cells and cervix cancer Hela cells were transfected with negative control miRNA (miR-NC) and
miR-30e mimic, and the cells were cultured and stained using EdU. Immunofluorescence images of EdU, a cell proliferation marker, were
analyzed in Kyse30 and Hela cells. (B) These cells were used to study cell invasion using the Transwell chambers with pre-coated Matrigel.
(C) Conditioned media were collected from Kyse30 and Hela cells overexpressing miR-30e and miR-NC. HUVECs were used to test tube
formation using the conditioned media obtained above. (D) Indicated cells were used for clonogenic assay. (E) Indicated cells were used for
colony formation assay. Data represent mean ± SD of 3 replicates. **indicates significant difference at P < 0.01.
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esophageal squamous cell carcinoma patients by Kaplan
Meier plotter analysis (Figure 4F). Taken together,
these results suggest that miR-30e suppresses tumor
growth and inhibits RPS6KB1 expression in vivo, and
RPS6KB1 acts as an oncogene in esophageal cancer.

we examined RPS6KB1 RNA levels in various tumor
tissues and adjacent healthy tissues using the RNA
sequencing data obtained from the TCGA database
(TIMER database, http://timer.comp-genomics.org/).
The results showed that RPS6KB1 levels were
upregulated in most types of cancer, including colon
adenocarcinoma, esophageal carcinoma, head and neck
squamous cell carcinoma, lung adenocarcinoma, lung
squamous cell carcinoma, stomach adenocarcinoma
(Figure 5A). We also used the GEPIA database
(http://gepia.cancer-pku.cn/index.html) to investigate
whether RPS6KB1 expression levels correlated with the

Analysis of RPS6KB1 and miR-30e expression levels
with overall survival and tumor progression in
several types of cancer
To determine whether RPS6KB1 expression levels are
upregulated in tumor tissues of other types of cancer,

Figure 3. RPS6KB1 was a novel target of miR-30e. (A) The miR-30e binding site predicted in the 3′-UTR of RPS6KB1 mRNA. Mutant
construct was generated at the seed sequence region of RPS6KB1 3′-UTR as indicated. The 3′-UTR fragment of RPS6KB1 mRNA containing
wild-type (WT) or mutant (MT) of the miR-30e binding site was cloned into pmirGLO vector. (B) Kyse30 cells were transfected with pmirGLO
reporter vector containing wild-type or mutant RPS6KB1 3′-UTR (indicated as RPS6KB1-WT and RPS6KB1-MT) with the combination of
either miR-NC or miR-30e mimic. Luciferase activities were determined 24 h after the co-transfection. (C, D) The protein levels of RPS6KB1
in Kyse30 and Hela cells were analyzed by Western blotting assay. The density levels of RPS6KB1 were determined by ImageJ software, and
relative fold changes were obtained by the ratios of RPS6KB1 to GAPDH levels. Data represent mean ±SD. of 3 replicates. *,**indicates
significant difference at P < 0.05, and at P < 0.01, respectively.

www.aging-us.com

24041

AGING

Figure 4. MiR-30e inhibited tumor growth and RPS6KB1 expression, and higher levels of RPS6KB1 were associated with
lower esophageal cancer survival rate. (A) Kyse30 cells were infected with lentivirus expressing miR-30e or miR-NC, and cells stably
expressing miR-NC and miR-30e termed as Kyse30/miR-NC and Kyse30/miR-30e were obtained after puromycin selection. Cells (5 × 106
cells) in 100 µl of serum-free DMEM medium were subcutaneously injected into posterior flanks on both sides of the nude mice (n = 5).
Tumors were measured every three days after they were visible starting on Day 12. Tumor volumes were calculated using the following
formula: volume = 0.5 × (length × width2). (B) Representative pictures of tumors. Bar = 2 mm. (C) The weights of tumors from miR-30e and
miR-NC groups were measured. (D) The total proteins were extracted from xenografts and subjected to Western blotting analysis to test
levels of RPS6KB1. GAPDH levels were used as an internal control. (E) The expression levels of RPS6KB1 and PCNA in tumor tissues were
analyzed by immunohistochemical (IHC) staining. (F) The Kaplan Meier plotter was used to detect the correlation between overall survival
(OS) and RPS6KB1 expression levels in esophageal adenocarcinoma and esophageal squamous cell carcinoma tissues, respectively. Data
represent mean ±SD of 3 replicates. *,**indicates significant difference at P < 0.05 and at P < 0.01, respectively.
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prognosis of cancer patients, and fount that RPS6KB1
expression levels significantly impacted the prognosis
of seven types of cancer, including breast, lung, ovarian
and liver cancers (Figure 5B). In order to determine

whether miR-30e expression levels are correlated with
cancer overall survival rate, we found that levels of
miR-30e expression were inversely correlated with the
patient survival in lung adenocarcinoma (LUAD), lung

Figure 5. Analysis of RPS6KB1 and miR-30e expression levels, overall patient survival rate and tumor progression in several
types of cancer. (A) Human RPS6KB1 levels in different types of tumor from TCGA were determined using TIMER database
(http://timer.comp-genomics.org/), and RPS6KB1 expression is upregulated in most types of tumor. (B) GEPIA (http://gepia.cancerpku.cn/index.html) was used to analyze the prognostic value of RPS6KB1 expression based on the log-rank test in 10 types of cancer. (C–F)
Kaplan-Meier plotter (http://kmplot.com/analysis/), an online database of published microarray datasets, was used to analyze the
correlation between miR-30e expression levels and overall patient survival in lung adenocarcinoma (LUAD), lung squamous cell carcinoma
(LUSC), bladder carcinoma and head and neck squamous cell carcinoma.
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squamous cell carcinoma (LUSC), bladder carcinoma
and head and neck squamous cell carcinoma using the
Kaplan-Meier plotter (http://kmplot.com/analysis/),
showing that higher miR-30e levels were associated
with better patient outcome (Figure 5C–5F).

These findings suggest the functional importance of
miR-30e/RPS6KB1 axis, and potential clinical
application by altering this pathway as new therapeutic
option for human EC therapy in the future.

MATERIALS AND METHODS

DISCUSSION

Cell culture and reagents
It is well-known that microRNAs alterations affect
expression of many genes that are important in the
initiation, maintenance and progression of human
cancers [10, 11, 27]. In this study, we found that miR30e expression was greatly downregulated in EC
patients. In the search of molecular mechanism of miR30e suppression, we found that RPS6KB1 is a direct
novel target of miR-30e, which may be important for
tumor development. RPS6KB1 has been identified as an
integrator of nutrient and growth factor signals for key
cellular processes such as cell proliferation, invasion,
and angiogenesis [22, 23]. In protein synthesis, it plays
an important role by interacting with or activating other
transcription factors [28]. Our results demonstrated that
forced expression of miR-30e dramatically suppressed
RPS6KB1expression at the protein level in human
esophageal cancer cell line Kyse30 and human cervical
cancer cell line HeLa. Growing evidence shows that
RPS6KB1 overexpression/activation is a critical driver
of initiation and progression of tumors, and that the
inactivation of RPS6KB1 may be therapeutically
effective in many types of cancer [29–32].

Human esophagus cancer Kyse30 cells, human cervical
cancer HeLa cells and human embryonic kidney 293T
cells were purchased from ATCC (Manassas, Virginia,
USA). Kyse30 cells were cultured in RPMI 1640
medium (Gibco), and HeLa and 293T cells were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco), with supplement of 10% fetal bovine
serum (FBS) and 100 U/mL penicillin, 100 μg/ml of
streptomycin (ThermoFisher Scientific, Waltham, MA).
Cells were maintained in a 37°C incubator with 5%
CO2.
Esophageal cancer specimens
Human esophageal cancer samples and adjacent normal
samples were obtained in the tissue bank of the Linzhou
Cancer Hospital, Henan, China. All patients received
informed written approval. The study was approved by
the Zhengzhou University Ethics Committee. All tissue
samples in the tissue bank of the institute were from the
patients who had undergone surgery and frozen
immediately in liquid nitrogen before analysis. The
samples we used for these experiments were obtained
without patient information from the tissue bank.

Recent studies have reported that the gain of function is
the central role of RPS6KB1 in resistance to tyrosine
kinase (TKI) in lung cancer, and its specific inhibitor
PF-4708671 shows synergistic effect to enhance TKIs
efficacy to suppress tumor growth in vivo [33]. Several
studies have shown that single reagent treatment often
fails in clinical practice, additional studies are necessary
to optimize combination therapies that include
RPS6KB1 inhibitor to treat EC. Our results here
showed that miR-30e suppression and RPS6KB1
upregulation were important in cell migration, colony
formation and tumor growth of cancer cells. We would
like to see if miR-30e/RPS6KB1 pathway would be new
target for EC clinical therapy by using combination of
cisplatin/pacilitaxel and miR-30e or RPS6KB1 inhibitor
PF-4708671 in the future.

EdU proliferation assay
The relative proliferation rates of cancer cells Kyse30
and HeLa were detected and analyzed with EdU
Imaging Kits using 5-ethynyl-2′-deoxyuridine (EdU,
from Riobio, China). Cells were seeded onto Millicell®
EZ SLIDE 8-well Slides (MilliporeSigma, Burlington,
MA) in medium with 10% FBS for 2–3 days. After
incubated with 10 μM EdU, cells in each well were
fixed. Permeability and DNA spotting were performed
in accordance with the protocol of the manufacturer.
Fluorescence microscopy was used to determine the
proportions of cells that incorporated EdU.

In conclusion, miR-30e was identified as a novel tumor
suppressor of EC. We further demonstrated that miR30e directly targeted RPS6KB1 by binding to its
3′-UTR and downregulation of miR-30e was implicated
in the progression of EC via RPS6KB1 overexpression.
More importantly, TCGA clinical evidence revealed
that both miR-30e and RPS6KB1 levels could be used
to predict prognosis and survival rate of EC patients.
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Clonogenic and colony formation assays
For clonogenic assay to test the ability of a single cell to
clone itself and grow into a full colony, single cells at
300 cells/well were seeded in 6-well plate and cultured
for about 2 weeks. Cells were washed, fixed and stained
with 0.05% violet crystal (Millipore Sigma, Burlington,
MA), and washed by 10% methanol at room
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temperature, and the pictures were taken by a camera.
For colony formation assay, single cells (300–500 per
well) were seeded in 6-well plate using SeaPlaque agar
with medium and cultured for 2–3 weeks. Then cells
were washed, stained with 0.01% violet crystal, and
washed by water at room temperature. The pictures
were taken using Nikon inverted microscope (Nikon
Instruments Inc., Melville, NY).

concentration was determined using a bicinchoninic
acid test and SDS-polyacrylamide gel electrophoresis
was used to analyze the protein extracts. The transfer
was performed in the transfer buffer (20 mM Tris, 150
mM Glycin, 20% methanol). The nitrocellulose
membranes were blocked with 5% non-fat milk for 2
hours prior to overnight incubation by first antibodies
against RPS6KB1 (Cell Signaling Technology,
Danvers, MA) and GAPDH (Bioworld, Nanjing,
China). The membranes were incubated by secondary
antibodies for 2 hours, washed, and protein bands were
visualized by the electrochemiluminescence detection
system (Thermo Fisher Scientific).

Cell invasion assay
1 × 105 Kyse30 and HeLa cells in serum-free medium
were seeded into Matrigel pre-coated Transwell upper
chamber (BD Bioscience, San Joes, CA) for cell invasion
analyses, and the complete medium with 10% FBS was
used as chemoattractant in the lower chamber. After 18–
24 hours of incubation, cells were stained with 0.05%
crystal violet in 10% methanol. Cells that didn’t go
through the pores were carefully removed with cotton
swab, then spotted cells were imaged and counted using a
microscope (Nikon Instruments Inc., Melville, NY).

Luciferase reporter assay
The pmirGLO vector (Promega, Madison and WI) was
used to insert specific fragments of miRNA target gene,
between SacI and XhoI restriction sites, which included
a wild-type or a mutant binding site of miR-30e. The
cells were cultured in 24-well plates and transfected
using Lipofectamine 3000 (Thermo Fisher Scientific,
Waltham, MA) according to instructions by the
manufacturers, with either wild type (WT) or mutant
type (mut) luciferase reporter plasmid and equal amount
of miR-30e mimic or miRNA negative control (miRNC). The luciferase activities were analyzed using the
Dual Luciferase Reporter Assay System (Promega,
Madison, WI) 24 hours after transfection.

Tube formation assay
Tube formation assay was performed as we previously
described [34]. Briefly, conditioned media from miRNC or miR-30e treated cells were collected. 2 × 104
HUVEC cells were suspended in the conditioned media
and seeded into Matrigel pre-coated 96-well plate. The
formation of tube-like structures was detected after 6–
12 hours. The length of tubal structures was counted
using Image J software. The results were expressed as
the medium ± SD from three independent experiments.
RNA
extraction,
quantitative PCR

RT-PCR,

and

Tumor grow assay
Six-week-old BALB/c (nu/nu) mice were purchased
from the Vital River Laboratory Animal Technology
(Beijing, China) and maintained under specific
pathogen free conditions at Zhengzhou University.
Mice were randomly divided into two groups
(5 mice/group) and subcutaneously injected 5 × 106
Kyse30/miR-NC or Kyse30/miR-30e cells to form
tumors. Mice were monitored 3 times/week for tumor
development and the size of tumors was measured with
calipers. Tumor volumes were calculated according to
the formula (width2 × length)/2. The mice were
sacrificed, xenografts were trimmed out and
photographed on Day 28 post-implantation. Tumor
sections were subjected to immunohistochemical
staining utilizing RPS6KB1 and PCNA antibodies. The
animal studies were approved by the Animal Care and
Use Committee at Zhengzhou University, and all animal
care and methodologies were in accordance with
institution guidelines.

real-time

The total RNAs were extracted and purified from cancer
cells and human tissues using TRIzol reagent, as
specified by the manufacturer (Thermo Fisher
Scientific, Waltham, MA). RT SuperMix reactions to
qPCR were carried out according to the manual
(Vazyme, China). The miR-30e qRT-PCR Primer Kit
(Riobio, China) was used to measure expressive levels
of miR-30e, and U6 expression was used as an internal
control. The quantitative RT-PCR on a QuantStudio 5
(Applied Biosystems) system was used to calculate the
fold changes by using SYBR Green Mix (Vazyme,
China), with relatively quantified methodology (2–ΔΔCt).
Protein extraction and immunoblotting
In an ice-cold radioimmunoprecipitation assay (RIPA)
complemented with protease inhibitors, cells or human
tissue were lysed for 30 minutes, then centrifuged at
13,000 rpm at 4°C for 15 minutes. The protein
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Statistical analysis
Data was shown as means ± SD from three replicates
and the results were analyzed using GraphPad Prism 8
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6. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A
Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J
Gastrointest Oncol. 2014; 6:112–20.
https://doi.org/10.4251/wjgo.v6.i5.112
PMID:24834141

(La Jolla). The student’s t-test was used to analyze the
quantitative variables between two groups with
significant differences at P < 0.05.
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SUPPLEMENTARY MATERIALS
Supplementary Figure

Supplementary Figure 1. Negative correlation between miR-30e and RPS6KB1 in various types of cancers. We analyzed the
relationship between miR-30e and RPS6KB1 in several types of cancers (http://www.linkedomics.org/admin.php). The results showed that
there was an inverse relationship between miR-30e and RPS6KB1 in breast invasive carcinoma (BRCA) (A), Glioblastoma multiforme (GBM)
(B), and lung adenocarcinoma (LUAD) (C).
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